According to the Pharmaceutical Investment Commissioner, the core competitiveness of pharmaceutical investment in pharmaceutical companies is reflected in: brand value, management ability, market control and government relations. The pharmaceutical industry is intellectually intensive, not capital-intensive, and the human factor is One person's ability determines the capabilities of the company. Good management can improve the core competitiveness of pharmaceutical companies. A good team can build the pharmaceutical business investment core competitiveness.
Under the new pharmaceutical market environment, pharmaceutical companies must rapidly build their core competitiveness in pharmaceutical investment promotion so that they can survive and thrive in one round of market competition. The pharmaceutical investment promotion strategy is a tactical investment decision for pharmaceuticals. It is a tactical judgement made after an in-depth analysis of controllable factors and uncontrollable factors, in order to increase the market share of pharmaceutical investment and the brand as the goal.
At present, companies are adopting the pharmaceutical investment promotion (4p), which is the product, price, channel, and promotion, when formulating the strategy for investment promotion. With the continuous development of pharmaceutical investment promotion practices, it is difficult to achieve the goals of pharmaceutical investment only by focusing on the “4p†basic pharmaceutical investment promotion factors that companies can control. Market research, market segmentation, target market selection, market positioning, and product positioning must be conducted on non-controllable factors and based on external environmental factors such as politics, economics, and culture.
In addition, in-depth investigations and scientific research are required to thoroughly grasp the market and provide scientific and rational medical investment promotion strategies. In the opinion of medical agent experts, pharmaceutical companies must implement strategic transformation of pharmaceutical investment, from simple product sales to corporate management level competitiveness. From now on, competitive environment, sales environment, competitors, policy environment, sales market, etc. will all change. Previous discussions have become impracticable, and timely strategic transformation to adapt to the new market pharmaceutical environment is the survival and development of pharmaceutical companies. only way.
The training for investment promotion cannot be in the form, and it must be based on "reality". The training plan must be well planned and a variety of training forms must be used before the training can be achieved. Pharmaceutical agency network analysis The practice of most pharmaceutical investment enterprises is: After selecting a distributor, the marketing department staff or sales staff will explain the product to the distributor's promotion staff. The selection of drugs must not fall into the homogenization of torrents. We must emphasize the characteristics of the varieties.
Under the new pharmaceutical market environment, pharmaceutical companies must rapidly build their core competitiveness in pharmaceutical investment promotion so that they can survive and thrive in one round of market competition. The pharmaceutical investment promotion strategy is a tactical investment decision for pharmaceuticals. It is a tactical judgement made after an in-depth analysis of controllable factors and uncontrollable factors, in order to increase the market share of pharmaceutical investment and the brand as the goal.
At present, companies are adopting the pharmaceutical investment promotion (4p), which is the product, price, channel, and promotion, when formulating the strategy for investment promotion. With the continuous development of pharmaceutical investment promotion practices, it is difficult to achieve the goals of pharmaceutical investment only by focusing on the “4p†basic pharmaceutical investment promotion factors that companies can control. Market research, market segmentation, target market selection, market positioning, and product positioning must be conducted on non-controllable factors and based on external environmental factors such as politics, economics, and culture.
In addition, in-depth investigations and scientific research are required to thoroughly grasp the market and provide scientific and rational medical investment promotion strategies. In the opinion of medical agent experts, pharmaceutical companies must implement strategic transformation of pharmaceutical investment, from simple product sales to corporate management level competitiveness. From now on, competitive environment, sales environment, competitors, policy environment, sales market, etc. will all change. Previous discussions have become impracticable, and timely strategic transformation to adapt to the new market pharmaceutical environment is the survival and development of pharmaceutical companies. only way.
The training for investment promotion cannot be in the form, and it must be based on "reality". The training plan must be well planned and a variety of training forms must be used before the training can be achieved. Pharmaceutical agency network analysis The practice of most pharmaceutical investment enterprises is: After selecting a distributor, the marketing department staff or sales staff will explain the product to the distributor's promotion staff. The selection of drugs must not fall into the homogenization of torrents. We must emphasize the characteristics of the varieties.
Ivacaftor Intermediates,Synthetic Drug Lumacaftor,High Purity Vx 809,Cas 936727-05-8
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com